1. Catalog
  2. Primary Prevention of ASCVD and T2DM in Patients a ...
Image For Activity Cover
Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline Educational Activity
Course Description
The dramatic increase in the prevalence of individuals at risk for the development of ASCVD and T2DM throughout the developed and developing world requires that physicians and other care providers are aware of the risk factors for these conditions and can identify individuals at risk in order to initiate treatment to prevent these diseases. The Endocrine Society has recognized the importance of identifying individuals who are at metabolic risk so that efforts can be instituted to prevent both ASCVD and T2DM. Several risk factors for ASCVD and T2DM—hypertension, lipid abnormalities, hyperglycemia, and abdominal adiposity—tend to cluster together. This clustering was originally known as the insulin resistance syndrome (IRS) because it was thought that insulin resistance was its underlying cause. However, although insulin resistance may be associated with these risk factors, it may not always be present and does not fully explain the syndrome. The term IRS has been replaced by combinations of clinical criteria that are defined differently by various organizations and attempt to describe a clinical entity, the metabolic syndrome. The major purpose was to use clinical signs and symptoms to identify people who have a combination of risk factors that contribute to a higher long-term risk for ASCVD and T2DM than that in the general population. The recent updated Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline addresses the population of individuals with components of the metabolic syndrome who do not yet have diagnosed ASCVD or T2DM and the steps that can be taken to prevent these two diseases. This short case-based online activity allows you to apply these recommendations to practice.
Target Audience
This content is for physicians and healthcare professionals seeking to remain up to date on the latest recommendations made by the Society for endocrine treatment of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk.
Learning Objectives
Apply the clinical practice guideline recommendations for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM) in individuals at metabolic risk for developing these conditions.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
 

The Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Lars F. Berglund, MD, PhD
University of California, Davis

Statement of Independence:  As a provider of CME accredited by the Accreditation Council for Continuing Medical Education (ACCME), Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force. 

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported financial relationships:

Lars F. Berglund, MD, PhD owns stocks with Boston Scientific, Gilead Schiences, Johnson & Johnson, Medtronic, Novo Nordisk, and Pfizer.

The medical editor for this program, Abbie L. Young, MS, CGC, ELS(D), reported no relevant financial relationships.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships

Summary
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274       
   
Android App Download IOS App Download Powered By